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Influence of Therapeutic Ceftiofur Treatments of Feedlot Cattle on
Fecal and Hide Prevalences of Commensal Escherichia coli Resistant to
Expanded-Spectrum Cephalosporins, and Molecular Characterization
of Resistant Isolates
John W. Schmidt,a Dee Griffin,b Larry A. Kuehn,a Dayna M. Brichta-Harhaya
U.S. Department of Agriculture, Agricultural Research Service, Roman L. Hruska U.S. Meat Animal Research Center, Clay Center, Nebraska, USAa; Great Plains Veterinary
Educational Center, School of Veterinary Medicine and Biomedical Sciences, University of Nebraska—Lincoln, Clay Center, Nebraska, USAb
In the United States, the blaCMY-2 gene contained within incompatibility type A/C (IncA/C) plasmids is frequently identified in
extended-spectrum-cephalosporin-resistant (ESCr) Escherichia coli strains from both human and cattle sources. Concerns have
been raised that therapeutic use of ceftiofur in cattle may increase the prevalence of ESCr E. coli. We report that herd ESCr E. coli
fecal and hide prevalences throughout the residency of cattle at a feedlot, including during the period of greatest ceftiofur use at
the feedlot, were either not significantly different (P > 0.05) or significantly less (P < 0.05) than the respective prevalences at
arrival. Longitudinal sampling of cattle treated with ceftiofur demonstrated that once the transient increase of ESCr E. coli shed-
ding that follows ceftiofur injection abated, ceftiofur-injected cattle were no more likely than untreated members of the same
herd to shed ESCr E. coli. Pulsed-field gel electrophoresis (PFGE) genotyping, antibiotic resistance phenotyping, screening for
presence of the blaCMY-2 gene, and plasmid replicon typing were performed on 312 ESC
r E. coli isolates obtained during six sam-
pling periods spanning the 10-month residence of cattle at the feedlot. The identification of only 26 unique PFGE genotypes, 12
of which were isolated during multiple sampling periods, suggests that clonal expansion of feedlot-adapted blaCMY-2 E. coli
strains contributed more to the persistence of blaCMY-2 than horizontal transfer of IncA/C plasmids between E. coli strains at this
feedlot. We conclude that therapeutic use of ceftiofur at this cattle feedlot did not significantly increase the herd prevalence of
ESCr E. coli.
Extended-spectrum cephalosporins (ESC) are critically impor-tant to human medicine and are frequently prescribed for the
treatment of invasive Escherichia coli and Salmonella enterica in-
fections (1–3). The blaCMY-2 gene, encoding the AmpC-like -lac-
tamase CMY-2, is frequently harbored by large (120-kbp) in-
compatibility type A/C (IncA/C) plasmids in ESC-resistant (ESCr)
E. coli and ESCr S. enterica strains isolated from human and animal
sources in the United States (4–13). IncA/C plasmids are consid-
ered broad-host-range plasmids since they have been identified in
many bacterial species, including Aeromonas, Escherichia, Kleb-
siella, Photobacterium, Salmonella, Vibrio, and Yersinia (14, 15).
IncA/C plasmids possess conserved backbone sequences, but the
sequences of genetic element insertions carrying antibiotic resis-
tance genes are often divergent (14, 16–18). However, the inser-
tions carrying genes conferring resistance to tetracyclines (tetA),
phenicols (floR), and streptomycin (aadA2) are generally con-
served between blaCMY-2 IncA/C plasmids harbored in E. coli and
S. enterica hosts (17, 18). Thus, it has been hypothesized that com-
mensal E. coli populations in the lower gastrointestinal systems of
cattle may serve as a reservoir of blaCMY-2 IncA/C plasmids, which
could then be transferred to more virulent food-borne pathogens,
including S. enterica (12, 18).
Ceftiofur (TIO) is an ESC approved for use in cattle to treat
several illnesses, including bovine respiratory disease complex.
The critical importance of ESC to human medicine along with
concerns that agricultural use of TIO may contribute to the occur-
rence of human ESCr infections factored into the European Food
Safety Authority recommendations to severely restrict or elimi-
nate TIO use in animal agriculture (19). Injection with TIO has
been demonstrated to transiently increase the fecal concentrations
of ESCr E. coli and blaCMY-2 in individual treated cattle (20–22).
The long-term impact of therapeutic TIO injection of cattle on
herd prevalence of ESCr E. coli is unclear since only two studies
have correlated TIO use (in dairy cattle herds sampled once or
twice) to ESC susceptibilities of commensal E. coli. One study
found an association between TIO use and isolation of E. coli with
reduced susceptibility to the ESC ceftriaxone (23), while the other
study found no association between extent of TIO use and ESCr E.
coli prevalence (24).
The factors contributing to long-term maintenance of ESCr E.
coli and the blaCMY-2 gene in the absence of TIO use are unclear. In
vitro experiments have demonstrated that carriage of blaCMY-2
IncA/C plasmids imposes a fitness cost on the host bacteria, lead-
ing to the conclusion that long-term maintenance of IncA/C plas-
mids requires selective pressure (25). A mathematical model of
ESCr E. coli populations in cattle suggests that E. coli strains har-
boring blaCMY-2 IncA/C plasmids could persist during periods of
low selective pressure even if they grow slower than other com-
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mensal E. coli strains if frequent horizontal transfer of blaCMY-2
IncA/C plasmids occurs or a sufficient fraction of E. coli bacteria
ingested by cattle contain blaCMY-2 IncA/C plasmids (26). Both E.
coli and S. enterica harboring blaCMY-2 IncA/C plasmids have been
isolated from diverse animal hosts in disparate geographic loca-
tions with varied exposure to antibiotics; thus, an undefined com-
bination of selective pressures, biological mechanisms, and pop-
ulation dynamics must ameliorate the fitness cost of blaCMY-2
IncA/C plasmid carriage (18). Isolation and characterization of
ESCr E. coli strains that persist in cattle production environments,
in the absence of TIO use, is required to further our understanding
of the factors that may contribute to the persistence of antibiotic
resistance.
The population of 763 cattle used in this study was raised on
pasture at the Roman L. Hruska U.S. Meat Animal Research Cen-
ter (USMARC) from birth until weaning, when they were trans-
ferred to the on-site feedlot. The USMARC maintains detailed
individual cattle health records, including all antibiotic treat-
ments. This population of cattle was not treated with subthera-
peutic levels of antibiotics. TIO was the preferred antibiotic for the
treatment of bovine respiratory disease complex (shipping fever),
infectious pododermatitis (foot rot), and infectious keratocon-
junctivitis (pink eye). Typically, cattle at the USMARC feedlot are
most susceptible to disease during the 4 to 6 weeks following
weaning and introduction to the feedlot. The most concentrated
use of therapeutic antibiotics occurs during this time, termed the
“period of increased disease susceptibility.” Following this period,
occurrences of illness and antibiotic use typically decline (Shuna
A. Jones [USMARC Veterinary Medical Officer], personal com-
munication).
This population of cattle presented an opportunity for a lon-
gitudinal study on the effects of TIO use on the prevalence and
persistence of ESCr E. coli. This cattle population also presented an
opportunity for the isolation and characterization of ESCr E. coli
prevalent in this cattle population during periods of limited TIO
use. Thus, the goals of this study were to (i) determine the fecal
and hide prevalences of ESCr E. coli for the cattle population from
feedlot arrival until shortly before harvest, (ii) determine the fecal
and hide prevalences of ESCr E. coli for the cattle injected with TIO
during the period of increased disease susceptibility from the day
of treatment to shortly before harvest, and (iii) characterize ESCr
E. coli cattle isolates obtained throughout the study with pulsed-
field gel electrophoresis (PFGE) genotyping, antibiotic resistance
phenotyping, plasmid size analysis, plasmid replicon typing, and
screening for presence of the blaCMY-2 gene.
MATERIALS AND METHODS
Study population and cattle sampling. The study population consisted of
763 cattle (403 steers and 360 heifers) born between 22 March 2009 and 16
June 2009 at USMARC and raised on pasture at USMARC until weaned,
when they were transferred to the USMARC feedlot between the dates of
25 September and 2 October 2009. The cattle then resided at the feedlot
until July 2010, when they were transported to harvest. Detailed records of
all antibiotics administered to study animals throughout their life span
were maintained, and no antibiotics were included in feed. Samples were
obtained during six periods, defined as follows: feedlot arrival (25 Sep-
tember 2009 to 2 October 2009), increased disease susceptibility (29 Sep-
tember 2009 to 30 October 2009), December 2009 (14 December 2009 to
22 December 2009), March 2010 (1 March 2010 to 5 March 2010), May
2010 (10 May 2010 to 13 May 2010), and July 2010 (13 July 2010 to 15 July
2010). Dates of the feedlot arrival and increased disease susceptibility
periods overlapped since cattle were introduced to the feedlot (and sam-
ples taken) over 5 days (on 25, 29, and 30 September 2009 and 1 and 2
October 2009), while therapeutic TIO injections at the feedlot began on 29
September 2009, before the entire studied population arrived at the feed-
lot. Three classes of samples were obtained during this study and are
described below, and the sampling scheme is illustrated in Fig. 1.
(i) Herd samples. At least 20% of the population of each pen was
sampled during the feedlot arrival (n  153), December 2009 (n  173),
March 2010 (n  178), May 2010 (n  178), and July 2010 (n  178)
periods. Cattle were selected for sampling using a random-number gen-
erator. During the period of increased disease susceptibility, 128 samples
were obtained over 4 days (9, 16, 23, and 30 October 2009); on each of
these days 32 cattle were sampled, two from each of the 16 pens containing
the study population. Cattle previously injected with TIO were excluded
from herd sampling during all six periods.
(ii) Cattle injected with TIO during the period of increased disease
susceptibility. Fifty cattle were injected with TIO during the increased
disease susceptibility period and were designated “IDSTIO” cattle. Pre-
TIO injection samples were obtained from 49 of these cattle. All cattle
injected with TIO during the increased disease susceptibility period were
held in a hospital pen until a follow-up health examination that occurred
3 to 8 days following injection. Post-TIO injection samples were obtained
from all 50 IDSTIO cattle during these follow-up health examinations.
Following completion of the follow-up health examination, all cattle were
returned to the pens they originally resided in, except for five cattle that
remained in the hospital pen since they required additional observation. A
total of 11 additional post-TIO injection samples were obtained from
these five cattle during additional health examinations that occurred be-
tween 9 and 20 days after the first TIO injection. During the December
2009 period, samples were obtained from 49 of the 50 IDSTIO cattle
since one of the injected cattle died prior to the December 2009 sampling.
During the March 2010, May 2010, and June 2010 periods, samples were
obtained from 48 of the 50 IDSTIO cattle since one of the injected cattle
died prior to the March 2010 sampling.
(iii) Cattle injected with TIO at times other than during the period of
increased disease susceptibility. Fifty-one cattle were injected with TIO
at times other than during the period of increased disease susceptibil-
ity and were termed “OtherTIO” cattle. Nineteen cattle were injected
with TIO prior to arrival at the feedlot, and samples were recovered
from eight of these cattle during the feedlot arrival period. Fourteen
additional cattle were injected with TIO between 1 November 2009
and 13 December 2009, for a total of 33 OtherTIO cattle, and all 33
were sampled during the December 2009 period. Six additional cattle
were injected with TIO between 23 December 2009 and 28 February
2010, for a total of 39 OtherTIO cattle, and all 39 were sampled
during the March 2010 period. Four additional cattle were injected
with TIO between 6 March 2010 and 9 May 2010, for a total of 43
OtherTIO cattle, and all 43 were sampled during the May 2010 pe-
riod. Eight additional cattle were injected with TIO between 14 May
2010 and 14 July 2010, for a total of 51 OtherTIO cattle, and all 51
were sampled during the July 2010 period.
Therapeutic antibiotic administration. During the life spans of the
study cattle (March 2009 to July 2010), there were 157 occasions of ther-
apeutic antibiotic administration (Table 1). One hundred thirty-seven
cattle were injected with antibiotics; 16 cattle were injected with antibiot-
ics on more than one occasion. During the life spans of the study cattle,
there were 110 therapeutic TIO injections (Table 1). One hundred one
cattle were injected with TIO; eight cattle received multiple TIO injec-
tions. The month with the highest number of TIO injections, 52, was
October 2009. During November 2009, there were 14 TIO injections ad-
ministered. From December 2009 through July 2010, 24 injections of TIO
were administered. There were 47 administrations of other therapeutic
antibiotics; the highest frequencies occurred in July 2009, with 16, and
September 2009, with 13 (Table 1).
Schmidt et al.
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Prevalence and enumeration of ESCr E. coli. Sample collection oc-
curred while cattle were restrained in a squeeze chute during vaccination,
health examination, therapeutic treatment, or routine weighing. Fecal
samples were collected by inserting a foam-tipped swab (catalog no.
10812-022; VWR International, Buffalo Grove, IL) 3 to 5 cm into the anus
of each animal. Immediately following fecal sample collection, the swab
was placed into 4 ml of tryptic soy broth (TSB) (Becton Dickinson, Sparks,
MD). Hide samples (1,000 cm2) were collected from each animal behind
the right shoulder with a sterile sponge (Nasco, Fort Atkinson, WI)
prewetted with 20 ml of buffered peptone water (BPW) (Becton Dickin-
son). Immediately following hide sampling, the sponge was placed into a
sterile bag. Fecal and hide samples were collected by different people, and
both changed gloves following each sample. Samples were processed
within 4 h of sampling. Fecal samples were suspended by vortexing at
maximum speed for 30 s. A 1-ml aliquot of suspended fecal matter was
removed and serially diluted in TSB. Hide sponge samples were hand
massaged for 15 s, and a 1-ml aliquot of suspension was removed and
serially diluted in BPW. Selected dilutions were spiral plated onto Mac-
Conkey agar (Becton Dickinson, Sparks, MD) containing no antibiotics
(MAC) and onto MacConkey agar supplemented with 4 mg liter1 of
cefotaxime (MACCTX). Cefotaxime was obtained from Sigma Co. (St.
Louis, MO). Plates were incubated overnight at 37°C. Pink to red colonies
on MAC plates were enumerated as lactose-fermenting coliforms. Pink to
red colonies on MACCTX were enumerated as presumptive ESCr E. coli.
Confirmation of presumptive ESCr E. coli isolates. Up to six pre-
sumptive ESCr E. coli isolates per sample were streaked onto MACCTX
plates and incubated at 37°C overnight. From each MACCTX streak
plate, a single isolated pink to red colony was selected and streaked onto a
Trypticase soy agar (TSA) plate (Becton Dickinson). One isolated colony
from each TSA streak was inoculated into a 0.7-ml tryptic soy broth (TSB)
(Becton Dickinson) culture contained in a 96-well block. Inoculated
blocks were incubated overnight at 37°C, followed by the addition of
glycerol to a final concentration of 15% to allow preservation at 80°C.
Prior to freezing, each culture was stamped onto five 150-mm TSA plates
with a 96-pin Boekel microplate replicator (Boekel Scientific, Feasterville,
PA) to screen for antibiotic resistance. The five plates were supplemented
FIG 1 Flow diagram of sampling scheme. Gray boxes indicate sampling periods. Vertical dashed line lines delineate sample classes. OtherTIO, cattle injected
with ceftiofur at times other than during the increased disease susceptibility period. IDSTIO, cattle injected with ceftiofur during the increased disease
susceptibility period.
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with antibiotics as follows: no additional antibiotics, 32 mg liter1 ampi-
cillin (AMP), 4 mg liter1 CTX, 64 mg liter1 kanamycin (KAN), 32 mg
liter1 nalidixic acid (NAL), or 32 mg liter1 tetracycline (TET). All an-
tibiotics were obtained from Sigma Co. Plates were incubated overnight at
37°C, and isolates were grouped into categories based on their growth on
the screened antibiotics. From each sample, at least one isolate from each
category was selected for biochemical confirmation of E. coli and PFGE.
Biochemical confirmation of E. coli was performed using the Sensititre
broth microdilution system and Gram-negative identification plates
(TREK Diagnostic Systems, Cleveland, Ohio) according to the manufac-
turers’ instructions. Samples with one or more presumptive ESCr E. coli
isolates confirmed as E. coli were designated ESCr E. coli prevalent.
PFGE. Pulsed-field gel electrophoresis (PFGE) analysis was performed
according to the protocol developed by the Centers for Disease Control
and Prevention (27). Agarose-embedded DNA was digested with XbaI
(New England BioLabs, Beverly, MA). Banding patterns were either clas-
sified as unique or grouped into clusters based on 90% homology using
BioNumerics software (Applied Maths, Sint-Martens-Latem, Belgium),
employing the Dice similarity coefficient with a 1.5% band position tol-
erance in conjunction with the unweighted-pair group method using
arithmetic averages for clustering.
Antibiotic susceptibility determinations. Antibiotic susceptibility
testing was performed using the Sensititre broth microdilution system
and CMV1AGNF plates (TREK Diagnostic Systems) to determine the
MIC for each of 15 antibiotic agents. The antimicrobials and breakpoints
for resistance in this panel were as follows: amikacin (AMI), 64 g ml1;
amoxicillin-clavulanic acid (AMC) 32/16 g ml1; AMP, 32 g ml1;
cefoxitin (FOX), 32 g ml1; TIO, 8 g ml1; ceftriaxone (AXO), 4
g ml1; chloramphenicol (CHL), 32 g ml1; ciprofloxacin (CIP), 4
g ml1; gentamicin (GEN), 16 g ml1; KAN, 64 g ml1; NAL,
32 g ml1; streptomycin (STR), 64 g ml1; sulfisoxazole (FIS),
512 g ml1; TET, 16 g ml1; and trimethoprim-sulfamethoxazole
(COT), 4/76 g ml1. Isolates resistant to three or more classes of
antibiotics were considered to be multidrug resistant (MDR). The antibi-
otic classes were as follows: aminoglycoside (AMI, GEN, KAN, and STR),
-lactam/-lactamase inhibitor combination (AMC), cephem (FOX,
TIO, and AXO), folate pathway inhibitor (FIS and COT), penicillin
(AMP), phenicol (CHL), quinolone (CIP and NAL), and tetracycline
(TET). The following organisms were used as quality control strains in the
antimicrobial sensitivity assays: Pseudomonas aeruginosa ATCC 27853, E.
coli ATCC 25922, and Staphylococcus aureus ATCC 25923.
Detection of the blaCMY-2 gene and 18 plasmid incompatibility
group replicons. Template DNA for PCR detection of the blaCMY-2 gene
and 18 plasmid incompatibility group (Inc) replicons was prepared by
combining 10 l of overnight culture of an isolated colony with 100 l of
BAX lysis buffer (DuPont Qualicon Inc., Wilmington, DE). Mixtures
were incubated at 37°C for 20 min, followed by incubation at 95°C for 10
min. Lysates were then cooled to room temperature on ice. Lysates were
subjected to PCR using the primers and conditions described by Kozak et
al. (28) to determine the presence or absence of the blaCMY-2 gene. Lysates
were subjected to multiplex PCRs using the primers and conditions de-
scribed by Johnson et al. (29) to determine the presence or absence of 18
plasmid Inc replicons (IncA/C, IncB/O, IncFIA, IncFIIA, IncFIB, IncFIC,
IncFrep, IncHI1, IncHI2, IncI1, IncK/B, IncL/M, IncN, IncP, IncT, IncW,
IncX, and IncY).
Plasmid size analysis. Plasmids were isolated using the method de-
scribed by Kado and Liu (30). Isolated plasmids were subjected to agarose
gel electrophoresis on 1% Tris-borate-EDTA agarose gels run for 4.5 h at
10 V cm1. Plasmid sizes were estimated relative to the BAC-Tracker
supercoiled DNA ladder (catalog no. BT010950; Epicentre Technologies
Corp., Madison, WI) and the supercoiled DNA ladder, 2 to 10 kb (catalog
no. G6231; Promega Corp., Madison, WI).
Statistics. Period ESCr E. coli prevalence values within a sample class
(herd, IDSTIO, or OtherTIO) and sample type (fecal or hide) were
compared using Pearson’s 2 with Bonferroni’s correction for multiple
comparisons, with P values of 0.05 considered significant. ESCr E. coli
TABLE 1 Individual therapeutic antibiotic treatments administered to members of the studied herd of 763 cattle
Mo and yr
No. of injections of indicated antibiotic(s)a Total no.
of
antibiotic
injections
No. of
animals
injected
with
antibioticsCeftiofur
Cloxacillin and
oxytetracycline Enrofloxacin Florfenicol
Florfenicol and
sulfadimethoxine Oxytetracycline Penicillin G Tulathromycin
March 2009 0 0 0 0 0 0 0 0 0 0
April 2009 0 1 0 1 0 0 0 0 2 2
May 2009 0 0 0 0 0 0 0 0 0 0
June 2009 1 0 0 0 1 0 0 0 2 2
July 2009 3 10 0 3 1 2 0 0 19 18b
August 2009 6 4 0 0 0 0 0 0 10 10
September 2009 10 8 0 0 0 3 2 0 23 23
October 2009 52 0 0 0 0 1 0 0 53 51c
November 2009 14 0 0 0 0 1 0 1 16 15d
December 2009 4 0 1 1 0 0 0 0 6 6
January 2010 0 0 0 0 0 5 0 0 5 5
February 2010 6 0 0 0 0 0 0 0 6 6
March 2010 3 0 0 0 0 0 0 0 3 3
April 2010 1 0 0 0 0 0 0 0 1 1
May 2010 3 0 0 0 0 0 0 1 4 4
June 2010 3 0 0 0 0 0 0 0 3 3
July 2010 4 0 0 0 0 0 0 0 4 4
Total over life spans
of herd cattle
(March 2009 to
July 2010)
110 23 1 5 2 12 2 2 157 137e
a Two antibiotics listed in the same column indicate injection of the same animal with both antibiotics simultaneously.
b In July 2009 an animal was injected with ceftiofur and then 3 days latter injected with oxytetracycline.
c Two animals each received two ceftiofur injections in October 2009.
d One animal received two ceftiofur injections in November 2009.
e One hundred thirty-seven cattle were injected with antibiotics, 16 cattle were injected with antibiotics on more than one occasion.
Schmidt et al.
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prevalence values from the same period were compared between sample
classes (herd versus IDSTIO and herd versus OtherTIO) using a two-
tailed Fisher exact test, with P values of 0.05 considered significant.
Comparisons of ESCr E. coli prevalence values from the same period be-
tween sample types (fecal versus hide samples) were performed using a
two-tailed Fisher exact test, with P values of 0.05 considered significant.
All comparisons were performed using the Compare2 program of the
WinPepi (ver. 11.7) package (31).
RESULTS
Herd prevalences and concentrations of ESCr E. coli. Only cattle
that had not received TIO injections were sampled to determine
the herd prevalences and concentrations of ESCr E. coli. When
cattle arrived at the feedlot, the herd ESCr E. coli prevalencesfecal
prevalence was 3.9% (Table 2). Subsequent herd ESCr E. coli fecal
prevalences ranged from 1.7 to 11.2%, but none of these preva-
lences differed significantly from the prevalence at arrival. The
highest herd fecal ESCr E. coli prevalence (11.2%) occurred in July
2010 and was significantly higher (P  0.05) than the December
2009, March 2010, and May 2010 (Table 2). Overall, 988 herd fecal
samples were obtained during this study, and concentrations of
ESCr E. coli that were 2.00 log CFU/swab were obtained from 22
samples (2.2%) (Table 2). These ESCr E. coli bacteria constituted
only a small fraction of the total fecal lactose-fermenting coliforms
shed; lactose-fermenting coliforms were enumerated from 984 of
the 988 (99.6%) of the herd fecal samples, and mean lactose-fer-
menting coliform concentrations by sample period ranged from
4.84 to 6.00 log CFU/swab (data not shown).
When cattle arrived at the feedlot, the ESCr E. coli hide preva-
lence was 15.0%, which was not different (P  0.05) than subse-
quent hide prevalences except the 1.7% prevalence during March
2010, which was significantly lower (P  0.05) than hide preva-
lences during all other periods except December 2009 (Table 2).
Overall, ESCr E. coli bacteria were enumerated on 100 hides, but
the hide concentrations of ESCr E. coli were 2.00 log CFU/100
cm2 for 79 (79.0%) of these samples (Table 2). The concentrations
of ESCr E. coli on the hides were low in comparison to the concen-
trations of lactose-fermenting coliforms present on the cattle
hides. Lactose-fermenting coliforms were enumerated from 980
of the 988 (99.2%) herd hide samples, with period mean concen-
trations of lactose-fermenting coliforms ranging from 3.11 to 4.66
log CFU/100 cm2 (data not shown).
Prevalences and concentrations of ESCr E. coli in feces and
on hides of cattle injected with TIO during the period of in-
creased disease susceptibility. During the period of increased dis-
ease susceptibility, 50 cattle were injected with TIO (“IDSTIO”
cattle). Pre-TIO injection samples were recovered from 49 of these
IDSTIO cattle, and the fecal prevalence of ESCr E. coli was 8.2%
(Table 3), which was not significantly different (P  0.50) than the
5.5% herd fecal prevalence of ESCr E. coli during the period of
increased disease susceptibility (see Table S1 in the supplemental
material). Post-TIO injection samples were obtained from all 50
IDSTIO cattle at 3 to 8 days following TIO injection, and the
fecal prevalence of ESCr E. coli of 92.0% was significantly higher
(P  0.05) than the 8.2% prevalence pre-TIO injection (Table 3).
The ESCr E. coli fecal prevalence post-TIO injection for IDSTIO
cattle was also significantly higher (P  0.01) than the 5.5% herd
fecal prevalence of ESCr E. coli during the period of increased
disease susceptibility (see Table S1 in the supplemental material).
For 11 additional samples obtained from five of these cattle during
subsequent health examinations that occurred during the in-
creased disease susceptibility period, the fecal prevalence of ESCr
E. coli was 90.9%. During the December 2009, March 2010, May
2010, and July 2010 sampling periods, the ESCr E. coli fecal prev-
alence ranged from 0.0 to 6.1% (Table 3) and did not significantly
differ (P  0.05) from the corresponding herd ESCr E. coli fecal
prevalences during these periods (see Table S1 in the supplemen-
tal material). The fecal concentrations of ESCr E. coli were 2.00
log CFU/swab for 52 of the 61 (85.2%) post-TIO injection samples
obtained during the period of increased disease susceptibility, but
fecal concentrations of ESCr E. coli were 2.00 log CFU/swab for
only 3 of the 193 (1.6%) samples obtained from these cattle during
the subsequent December 2009, March 2010, May 2010, and July
2010 sampling periods (Table 3).
The 26.0% hide prevalence of ESCr E. coli for IDSTIO cattle
sampled at 3 to 8 days post-TIO injection was higher than the
8.2% prevalence pre-TIO injection, but this difference was not
statistically significant (Table 3). ESCr E. coli hide prevalences for
IDSTIO cattle were not significantly different than the pre-TIO
injection hide prevalence during the December 2009, March 2010,
May 2010, and July 2010 periods but ranged from 24.5 and 20.4%
during December 2009 and May 2010 to 0.0% during March 2010
and July 2010 (Table 3). Hide concentrations of ESCr E. coli were
TABLE 2 Qualitative and quantitative evaluation of ESCr E. coli for a cattle herd residing at a feedlot
Period
No.
sampled
Fecal samples Hide samples
% ESCr
E. coli
prevalence
(frequency)a
No. of samples in each class of log CFU/swab
values
% ESCr
E. coli
prevalence
(frequency)a
No. of samples in each class of log
CFU/100 cm2 values
1.70 to
1.99
2.00 to
2.99
3.00 to
3.99
4.00 to
4.99 4.99
1.30 to
1.99
2.00 to
2.99
3.00 to
3.99 3.99
Feedlot arrival 153 3.9 (6) AB 2 2 1 0 1 15.0 (23) A 16 6 1 0
Increased disease
susceptibility
128 5.5 (7) AB 2 4 0 1 0 11.7 (15) A 14 1 0 0
December 2009 173 2.9 (5) B 3 1 1 0 0 7.5 (13) AB 3 8 2 0
March 2010 178 1.7 (3) B 1 1 1 0 0 1.7 (3) B 3 0 0 0
May 2010 178 2.2 (4) B 3 1 0 0 0 17.4 (31) A 28 2 1 0
July 2010 178 11.2 (20) A 12 8 0 0 0 8.4 (15) A 15 0 0 0
Total 988 4.6 (45) 23 17 3 1 1 10.1 (100) 79 17 4 0
a Prevalence values in the same column that do not have a common letter are statistically significantly different (P  0.05).
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2.00 log CFU/100 cm2 for only 13 of the 303 (4.3%) hide sam-
ples obtained from IDSTIO cattle (Table 3). Pre-TIO injection,
March 2010, May 2010, and July 2010 hide ESCr E. coli prevalences
for IDSTIO were not significantly different (P  0.05) from
their corresponding herd ESCr E. coli hide prevalences during
these periods (see Table S1 in the supplemental material). How-
ever, the 26.0% hide prevalence of ESCr E. coli for IDSTIO cattle
sampled at 3 to 8 days post-TIO injection was significantly higher
(P  0.02) than the herd ESCr E. coli hide prevalence of 11.7%
during the period of increased disease susceptibility (see Table S1
in the supplemental material). During December 2009, the 24.5%
ESCr E. coli hide prevalence for IDSTIO cattle was significantly
higher (P  0.01) than the herd ESCr E. coli hide prevalence of
7.5% (see Table S1 in the supplemental material).
Prevalences and concentrations of ESCr E. coli in feces and
on hides of cattle injected with TIO at times other than during
the period of increased disease susceptibility. Cattle that had
been injected with TIO at times other than during the period of
increased disease susceptibility (“OtherTIO” cattle) were sam-
pled during the feedlot arrival, December 2009, March 2010, May
2010, and July 2010 sampling periods. During the feedlot arrival
period, samples were obtained from eight of the 19 cattle that had
been injected with TIO while on pasture, and ESCr E. coli was
isolated from one fecal sample and one hide sample, which were
not from the same animal (Table 4). The number of OtherTIO
cattle sampled increased during each subsequent period, from 33
during December 2009 to 51 during July 2010, since TIO injec-
tions continued to occur during the residence of the herd at the
feedlot (Table 1). ESCr E. coli fecal prevalences for the samples
obtained from December to July ranged from 0.0 to 9.8%. Fecal
concentrations of ESCr E. coli were 2.00 log CFU/swab for only
two of the 174 (1.1%) samples obtained from OtherTIO cattle
(Table 4). Prevalences of ESCr E. coli on the hides of OtherTIO
cattle were 9.1, 2.6, 25.6, and 3.9%, during December 2009, March
2010, May 2010, and July 2010, respectively (Table 4). Hide con-
centrations were 2.00 log CFU/100 cm2 for only 3 of the 174
(1.7%) hide samples obtained from these cattle. ESCr E. coli prev-
alences for OtherTIO cattle did not significantly differ (P 
0.05) from their corresponding herd prevalences during the De-
cember 2009, March 2010, May 2010, and July 2010 periods for
both fecal and hide samples (see Table S2 in the supplemental
material).
TABLE 3 Qualitative and quantitative evaluation of ESCr E. coli for cattle injected with ceftiofur during the increased disease susceptibility period
Period
No.
sampled
Fecal samples Hide samples
% ESCr
E. coli
prevalence
(frequency)a
No. of samples in each class of log CFU/swab values % ESC
r
E. coli
prevalence
(frequency)a
No. of samples in each class of log CFU/
100 cm2 values
1.70 to
1.99
2.00 to
2.99
3.00 to
3.99
4.00 to
4.99 4.99
1.30 to
1.99
2.00 to
2.99
3.00 to
3.99 3.99
Increased disease susceptibility,
pre-ceftiofur injection
49 8.2 (4) B 0 4 0 0 0 8.2 (4) AB 2 2 0 0
Increased disease susceptibility,
3 to 8 days post-ceftiofur
injection
50 92.0 (46) A 3 19 17 6 1 26.0 (13) A 10 1 2 0
Increased disease susceptibility,
additional post-ceftiofur
injection samples
11 90.9 (10) 1 3 5 1 0 27.3 (3) 1 2 0 0
December 2009 49 6.1 (3) B 1 1 0 1 0 24.5 (12) A 7 5 0 0
March 2010 48 0.0 (0) B 0 0 0 0 0 0.0 (0) B 0 0 0 0
May 2010 48 2.1 (1) B 0 1 0 0 0 20.8 (10) A 9 1 0 0
July 2010 48 2.1 (1) B 1 0 0 0 0 0.0 (0) B 0 0 0 0
Total 303 21.5 (65) 6 28 22 8 1 13.9 (42) 29 11 2 0
a Prevalence values in the same column that do not have a common letter are statistically significantly different (P  0.05). Prevalences for increased disease susceptibility with
additional post-ceftiofur injection samples were not included in statistical comparisons.
TABLE 4 Qualitative and quantitative evaluation of ESCr E. coli for cattle injected with ceftiofur at times other than during the increased disease
susceptibility period
Period
No.
sampled
Fecal samples Hide samples
% ESCr
E. coli
prevalence
(frequency)a
No. of samples in each class of log CFU/swab
values
% ESCr
E. coli
prevalence
(frequency)a
No. of samples in each class of log
CFU/100 cm2 values
1.70 to
1.99
2.00 to
2.99
3.00 to
3.99
4.00 to
4.99 4.99
1.30 to
1.99
2.00 to
2.99
3.00 to
3.99 3.99
Feedlot arrival 8 12.5 (1) 1 0 0 0 0 12.5 (1) 1 0 0 0
December 2009 33 3.0 (1) A 1 0 0 0 0 9.1 (3) AB 1 2 0 0
March 2010 39 0.0 (0) A 0 0 0 0 0 2.6 (1) B 1 0 0 0
May 2010 43 0.0 (0) A 0 0 0 0 0 25.6 (11) A 10 1 0 0
July 2010 51 9.8 (5) A 3 2 0 0 0 3.9 (2) B 2 0 0 0
Total 174 4.0 (7) 5 2 0 0 0 10.3 (18) 15 3 0 0
a Prevalence values in the same column that do not have a common letter are statistically significantly different (P  0.05). Feedlot arrival prevalences were not included in
statistical comparisons.
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PFGE genotypes of ESCr E. coli isolates. XbaI PFGE genotypes
were obtained for 383 ESCr E. coli isolates. Genotypes were ob-
tained for 198 fecal isolates originating from 113 samples; thus, for
40 of the fecal samples more than one isolate was genotyped. Ge-
notypes were obtained for 185 hide isolates originating from 158
samples; thus, more than one isolate was genotyped for 25 hide
samples. Multiple XbaI PFGE banding patterns were identified
from 39 of 65 samples that had more than one isolate genotyped
(37 samples had 2 banding patterns, and 2 samples had 3 banding
patterns). Seventy-one isolates had XbaI PFGE banding patterns
identical to that of another isolate from the same sample and were
considered redundant. Of the 312 nonredundant isolates, 133
originated from feces and 179 originated from hides. Overall, 26
unique XbaI PFGE banding patterns were identified, and these
genotypes were assigned letters according to their prevalence (i.e.,
genotype A was most prevalent, followed by genotype B, etc.).
Eight genotypes (S, T, U, V, W, X, Y, and Z) were identified from
only one sample. Of the 18 genotypes identified from more than
one sample, two (P and R) were identified exclusively from fecal
samples, and two (I and L) were identified exclusively from hide
samples (Table 5).
The overall most prevalent genotype, genotype A, was identi-
fied from 101 of the 271 (37.3%) ESCr E. coli-positive samples.
Genotype A was predominate in fecal samples, since it was iden-
tified in 66 of the 113 (58.4%) ESCr E. coli-positive fecal samples.
The next most prevalent fecal genotype (genotype C) was isolated
from only 18 (15.9%) of the ESCr E. coli-prevalent fecal samples.
No single genotype predominated in ESCr E. coli-prevalent hide
samples, since genotypes B, A, D, and E were prevalent in 40
(25.3%), 35 (22.2%), 22 (13.9%), and 19 (12.0%) of the 158 ESCr
E. coli-positive hide samples, respectively. No genotype was iso-
lated during all six sampling periods, but pattern A was prevalent
during five of the six sampling periods, all except December 2009
(Table 5). Other genotypes prevalent during multiple sampling
periods were C, E, L, and N, each being prevalent during three
sampling periods. Genotypes B, F, G, H, J, K, and R were each
prevalent during two sampling periods (Table 5).
Antibiotic resistance phenotypes of ESCr E. coli isolates. Sus-
ceptibilities to 15 antibiotics were determined for the 312 nonre-
dundant ESCr E. coli isolates. All isolates were MDR, since all
were resistant to at least three classes of antibiotics. All isolates
were susceptible to AMI and CIP. Seven resistance phenotypes
were identified. Resistance to at least AMC, AMP, FOX, TIO,
AXO, CHL, STR, FIS, and TET (ACSSuTAuCfCtCx phenotype)
was detected with 99.7% (n  311) of isolates (Table 6). One
isolate was susceptible to CHL but resistant to AMC, AMP, FOX,
TIO, AXO, STR, FIS, and TET. For 13 of 14 genotypes with more
than four isolates examined, the predominate resistance pheno-
type was observed for 75% of the isolates; genotype F was the
only exception. Notably, all eight genotype F isolates with the
ACSSuTAuCfCtCx  NAL resistance phenotype were from sam-
ples from the increased disease susceptibility period, while all six
genotype F isolates with the ACSSuTAuCfCtCx  KAN  NAL
resistance phenotype were from May 2010 samples (data not
shown).
Prevalence of the blaCMY-2 gene, plasmid replicons, and plas-
mids of >80 kbp in ESCr E. coli isolates. The blaCMY-2 gene was
present in all 312 nonredundant ESCr E. coli isolates. The plasmid
replicons IncB/O, IncFIIA, IncFIC, IncHI1, IncHI2, IncK/B,
IncL/M, IncP, IncT, IncW, and IncX were not detected from any
isolate. The IncA/C replicon was the most prevalent replicon, be-
ing present in 69.2% (n  216) of isolates (Table 7). Interestingly,
all 97 isolates lacking the IncA/C plasmid replicon were genotype
A (the IncA/C plasmid replicon was detected from only 5 of the
101 genotype A isolates). The next most prevalent plasmid repli-
con was IncY, present in 23.4% (n  73) of the isolates. The Inc-
FIB plasmid replicon was present in 20.2% (n  63) of the isolates,
and its presence was correlated with COT resistance, since 76.2%
of the isolates with the IncFIB replicon were COT resistant and
82.8% of COT-resistant isolates possessed the IncFIB replicon
(data not shown). One or more plasmids larger than 80 kbp were
present in 68.9% (n  215) of the 312 nonredundant ESCr E. coli
isolates (Table 7). Of the 97 isolates lacking a plasmid larger than
80 kbp, 95 were genotype A isolates. A single 4-kbp plasmid was
TABLE 5 ESCr E. coli PFGE genotype prevalences
Sample type and period
No. of
isolates
PFGE genotype frequency
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Fecal samples
Feedlot arrival 7 1 6
Increased disease susceptibility 78 36 17 1 1 6 2 2 3 1 1 2 1 1 1 1 1 1
December 2009 12 2 1 2 2 3 1 1
March 2010 3 1 1 1
May 2010 5 4 1
July 2010 28 24 1 1 1 1
Total 133 66 2 18 6 4 1 7 3 4 5 4 2 1 2 1 2 1 1 1 1 1
Hide samples
Feedlot arrival 25 22 2 1
Increased disease susceptibility 42 13 14 7 1 1 1 1 1 1 1 1
December 2009 28 19 5 3 1
March 2010 4 2 2
May 2010 63 8 39 1 6 9
July 2010 17 14 1 1 1
Total 179 35 40 15 22 19 13 2 6 9 3 1 5 1 3 1 1 1 1 1
Total (fecal and hide) 312 101 42 33 28 23 14 9 9 9 7 6 5 5 5 2 2 2 2 1 1 1 1 1 1 1 1
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the only plasmid present in 89.1% (n  90) of the genotype A
isolates (data not shown).
DISCUSSION
A goal of this study was to determine the prevalence and levels of
ESCr E. coli in a feedlot cattle population when TIO was the pre-
ferred therapeutic antibiotic. TIO injection is known to tran-
siently increase the fecal concentrations of ESCr E. coli and
blaCMY-2 in individual cattle before returning to levels observed
prior to TIO injection (20–22). During the December 2009,
March 2010, May 2010, and June 2010 sample periods, fecal prev-
alences of ESCr E. coli for IDSTIO or OtherTIO cattle were not
significantly higher (P  0.05) than the corresponding herd fecal
prevalences (see Tables S1 and S2 in the supplemental material).
This result demonstrates that once the transient increase of ESCr
E. coli shedding that follows TIO injection abates, TIO-injected
cattle are no more likely than untreated members of the same herd
to shed ESCr E. coli. Two prior studies of the impact of TIO use on
the prevalence of ESCr E. coli in dairy cow herds had conflicting
results, with one study finding an association and the other finding
no association between the extent of TIO use and herd prevalence
of E. coli with reduced susceptibility to ESC (23, 24). In this study,
herd fecal and hide ESCr E. coli prevalences when weaning calves
arrived at the feedlot were not significantly lower (P  0.05) than
prevalences during any subsequent sampling period (Table 2).
This suggests that the therapeutic use of TIO in feedlot cattle pop-
ulations does not significantly increase the herd prevalence of
ESCr E. coli. However, we note that differences exist between the
practices of the USMARC feedlot and those of commercial feed-
lots. Specifically, the USMARC cattle populations are “closed”
(i.e., all feedlot cattle are born on center and raised until weaned
on USMARC pastures, and replacement heifers are selected from
USMARC populations), and introduction of cattle to USMARC
feedlot occurs only twice per year when weaning calves are trans-
ferred to the feedlot. Thus, patterns of therapeutic antibiotic use in
some commercial feedlots may differ from those in the USMARC
feedlot.
E. coli strains associated with cattle are known to harbor anti-
biotic resistance genes, including genes encoding ESCr (5, 32–36).
These antibiotic resistance genes may be transmitted to human
commensal and pathogenic bacteria, either by E. coli or when hor-
izontally transferred to food-borne pathogenic bacteria, such as S.
enterica (5, 37, 38). Therefore, fecal samples are typically exam-
ined to assess ESCr E. coli or blaCMY-2 presence in cattle environ-
ments (20–24, 39). Hide samples were cultured for ESCr E. coli,
since hides have been demonstrated to harbor E. coli strains of
fecal origin, including E. coli O157:H7 (40, 41). During this study,
a total of 1,465 fecal and 1,465 hide samples were obtained, and
blaCMY-2 positive ESC
r E. coli was prevalent on 10.9% (n  160) of
hides, which is significantly higher (P  0.01) than the 8.0% (n 
117) prevalence in feces (data not shown). The 92.0% (n  46)
TABLE 6 Antibiotic resistance phenotypes of ESCr E. coli isolates
PFGE
genotype
No. of
isolates
% of isolates with resistance to the indicated antibioticsa
AMC, AMP, FOX,
AXO, TIO, STR,
FIS, TET
AMC, AMP, FOX,
AXO, TIO, CHL,
STR, FIS, TET
AMC, AMP, FOX,
AXO, TIO, CHL,
NAL, STR, FIS,
TET
AMC, AMP, FOX,
AXO, TIO, CHL,
STR, FIS, TET,
COT
AMC, AMP, FOX,
AXO, TIO, CHL,
NAL, STR, FIS,
TET, COT
AMC, AMP, FOX,
AXO, TIO, CHL,
KAN, NAL, STR,
FIS, TET
AMC, AMP, FOX,
AXO, TIO, CHL,
GEN, KAN, STR,
FIS, TET
A 101 0.0 97.0 2.0 1.0 0.0 0.0 0.0
B 42 0.0 0.0 97.6 0.0 0.0 2.4 0.0
C 33 0.0 3.0 0.0 90.9 6.1 0.0 0.0
D 28 0.0 100.0 0.0 0.0 0.0 0.0 0.0
E 23 0.0 13.0 0.0 0.0 87.0 0.0 0.0
F 14 0.0 0.0 57.1 0.0 0.0 42.9 0.0
G 9 0.0 100.0 0.0 0.0 0.0 0.0 0.0
H 9 0.0 100.0 0.0 0.0 0.0 0.0 0.0
I 9 0.0 77.8 22.2 0.0 0.0 0.0 0.0
J 7 0.0 85.7 0.0 0.0 14.3 0.0 0.0
K 6 0.0 100.0 0.0 0.0 0.0 0.0 0.0
L 5 0.0 0.0 0.0 0.0 0.0 0.0 100.0
M 5 0.0 100.0 0.0 0.0 0.0 0.0 0.0
N 5 0.0 100.0 0.0 0.0 0.0 0.0 0.0
O 2 0.0 0.0 0.0 100.0 0.0 0.0 0.0
P 2 0.0 100.0 0.0 0.0 0.0 0.0 0.0
Q 2 0.0 100.0 0.0 0.0 0.0 0.0 0.0
R 2 0.0 100.0 0.0 0.0 0.0 0.0 0.0
S 1 0.0 0.0 100.0 0.0 0.0 0.0 0.0
T 1 0.0 100.0 0.0 0.0 0.0 0.0 0.0
U 1 0.0 100.0 0.0 0.0 0.0 0.0 0.0
V 1 0.0 0.0 0.0 0.0 0.0 0.0 100.0
W 1 0.0 100.0 0.0 0.0 0.0 0.0 0.0
X 1 100.0 0.0 0.0 0.0 0.0 0.0 0.0
Y 1 0.0 100.0 0.0 0.0 0.0 0.0 0.0
Z 1 0.0 0.0 0.0 100.0 0.0 0.0 0.0
Total 312 0.3 59.9 17.3 10.9 7.4 2.2 1.9
a Antibiotics: AMC, amoxicillin-clavulanic acid; AMP, ampicillin; FOX, cefoxitin; AXO, ceftriaxone; TIO, ceftiofur; CHL, chloramphenicol; GEN, gentamicin; KAN, kanamycin;
NAL, nalidixic acid; STR, streptomycin; FIS, sulfisoxazole; TET, tetracycline; COT, trimethoprim-sulfamethoxazole.
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fecal prevalence of ESCr E. coli for IDSTIO at 3 to 8 days post-
TIO was significantly higher (P  0.01) than the 26.0% (n  16)
hide prevalence for these cattle (Table 3). Genotype prevalences
also differed between fecal and hide samples; for example, geno-
type B was the most prevalent hide genotype during May 2010
(isolated from 39 hides) but was isolated from only one May 2010
fecal sample (Table 5). Prevalence and genotype distribution dif-
ferences between fecal and hide samples were expected, since fecal
samples recover the E. coli population shed by the animal at the
moment of sampling, while the hide sample obtained from the
same animal likely contains a more broad representation of
the overall E. coli population present in the feedlot environment at
the time of sampling. These results demonstrate that hide sam-
pling is a useful complement to fecal sampling for examination of
the antibiotic resistance status of commensal E. coli in cattle feed-
lot environments.
To our knowledge, ESCr E. coli isolated from a longitudinal
study of a single cattle herd had not been subjected to genotypic
analysis. In this study, we identified only 26 ESCr E. coli genotypes,
12 of which were isolated during multiple sampling periods, and
we identified a predominant genotype (A) which was isolated dur-
ing five of the six sampling periods (Table 5). Our results suggest
that clonal expansion of feedlot-adapted E. coli strains containing
blaCMY-2 contributes to the persistence of the ESC
r E. coli in this
cattle herd. We note that Daniels et al. identified 46 unique geno-
types from 46 blaCMY-2 ESC
r E. coli isolates obtained from 14 cattle
herds, suggesting that blaCMY-2 ESC
r E. coli populations between
herds are diverse (7). Consideration of the results of this study, the
study by Daniels et al., and the mathematical modeling of the
persistence of blaCMY-2 ESC
r E. coli in cattle environments per-
formed by Volkova et al. (26), it is likely that both conjugal trans-
fer and clonal expansion contribute to blaCMY-2 IncA/C plasmid
persistence in commensal E. coli. We note that E. coli has been
demonstrated to survive for at least 6 months in cattle fecal pats
(42, 43) and for at least 6 weeks on feedlot surfaces after the re-
moval of cattle (44). Thus, we theorize that in individual feedlots,
persistence of blaCMY-2 ESC
r E. coli occurs primarily by a cycle of
ingested and shed clonal populations “adapted” to survive the
specific stresses encountered in cattle and the environment at the
individual feedlot level. We further theorize that conjugal transfer
also occurs, ensuring that blaCMY-2 IncA/C plasmids are trans-
ferred to other receptive commensal E. coli strains, which are pos-
sibility more fit to survive when the environmental conditions
change. Longitudinal studies of multiple cattle feedlots are re-
quired to test these theories of blaCMY-2 ESC
r E. coli persistence in
cattle feedlots.
All genotype A isolates possessed the ACSSuTAuCfCtCx
phenotype, typically conferred by large blaCMY-2 IncA/C plasmids,
but 89.1% of these isolates had only one 4-kbp plasmid, which is
not large enough to carry all of the resistance genes (blaCMY-2, tetA,
floR, aadA2, sul1, and sul2) typically harbored by blaCMY-2 IncA/C
plasmids. Additionally, the IncA/C replicon was detected from
only 5.0% of the genotype A isolates (Table 7). A few scenarios
could explain these results. The integration of different genetic
elements harboring the blaCMY-2 gene and the genes conferring the
other antibiotic resistances could have occurred independently.
TABLE 7 Prevalence of plasmids 80 kbp and replicons in ESCr E. coli isolates
PFGE
genotype
No. of
isolates
% of isolates with at
least one plasmid
80 kbp
% of isolates with indicated replicon
IncA/C IncY IncFIB IncFrep IncFIA IncN IncI1
A 101 5.9 5.0 12.9 4.0 0.0 2.0 4.0 4.0
B 42 100.0 100.0 0.0 0.0 0.0 0.0 0.0 0.0
C 33 100.0 100.0 39.4 84.8 48.5 3.0 6.1 3.0
D 28 100.0 100.0 100.0 0.0 3.6 100.0 0.0 0.0
E 23 100.0 100.0 4.3 78.3 0.0 0.0 0.0 0.0
F 14 100.0 100.0 0.0 0.0 85.7 0.0 0.0 0.0
G 9 100.0 100.0 100.0 0.0 0.0 0.0 11.1 0.0
H 9 88.9 100.0 11.1 44.4 22.2 0.0 0.0 0.0
I 9 100.0 100.0 0.0 0.0 66.7 0.0 100.0 0.0
J 7 100.0 100.0 0.0 28.6 14.3 0.0 0.0 0.0
K 6 100.0 100.0 0.0 0.0 0.0 0.0 0.0 0.0
L 5 100.0 100.0 60.0 20.0 100.0 40.0 20.0 0.0
M 5 100.0 100.0 0.0 0.0 0.0 0.0 0.0 0.0
N 5 100.0 100.0 0.0 100.0 0.0 100.0 0.0 0.0
O 2 100.0 100.0 50.0 0.0 0.0 50.0 0.0 0.0
P 2 100.0 100.0 0.0 0.0 50.0 0.0 0.0 0.0
Q 2 100.0 100.0 100.0 0.0 0.0 0.0 0.0 0.0
R 2 100.0 100.0 0.0 0.0 0.0 0.0 0.0 0.0
S 1 100.0 100.0 0.0 0.0 0.0 0.0 0.0 0.0
T 1 100.0 100.0 0.0 0.0 0.0 0.0 0.0 0.0
U 1 100.0 100.0 0.0 0.0 0.0 0.0 0.0 0.0
V 1 100.0 100.0 100.0 0.0 0.0 0.0 0.0 0.0
W 1 100.0 100.0 0.0 0.0 0.0 0.0 100.0 0.0
X 1 0.0 100.0 0.0 0.0 100.0 0.0 0.0 0.0
Y 1 100.0 100.0 0.0 0.0 0.0 0.0 0.0 0.0
Z 1 100.0 100.0 100.0 100.0 0.0 0.0 0.0 0.0
Total 312 68.9 69.2 23.4 20.2 14.4 12.5 5.8 1.6
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Indeed, presence of blaCMY-2 in the bacterial chromosome is not
unprecedented, since a blaCMY-2 gene is contained within a chro-
mosomally integrated SXT/R391-like element in a human clinical
isolate of Proteus mirabilis (45). However, since all genotype A
isolates had the ACSSuTAuCfCtCx phenotype, a more likely
explanation is integration of a blaCMY-2 IncA/C plasmid into the E.
coli chromosome. Failure to detect the IncA/C replicon can be
explained if the plasmid site of integration was located between
the annealing sites of the primers used to amplify the IncA/C rep-
licon. Alternatively, the plasmid site of integration could be lo-
cated elsewhere, but one of the primer annealing sites may have
been altered by mutation, insertion, or deletion.
Concerns have been raised that therapeutic use of TIO in ani-
mal agriculture, including its use in feedlot cattle, contributes sig-
nificantly to the increased occurrence of ESCr infections in hu-
mans (2, 19, 46, 47). The isolation of blaCMY-2 ESC
r E. coli from
U.S. retail beef supports these concerns, but the source of the ESCr
E. coli in these products is unknown (4). However, it is well estab-
lished that the primary source of contamination of beef products
with S. enterica and E. coli O157:H7 during processing are cattle
hides with high levels of these pathogens (40, 41, 48, 49). The July
2010 hide samples were obtained within 2 weeks of harvest and
approximate the population of ESCr E. coli likely to be present on
the hides of these cattle during processing. Herd prevalence of
ESCr E. coli on hides was 8.4% in July 2010, but ESCr E. coli con-
centrations were 2.00 log CFU/100 cm2 for all of these samples
(Table 2). Thus, the ESCr E. coli likely present on these cattle hides
when sent to harvest was a very small fraction of the overall lac-
tose-fermenting coliform population on the hides, since the herd
prevalence of lactose-fermenting coliforms on hides during July
2010 was 100% and the mean concentration was 4.60 log CFU/100
cm2 (data not shown). Complex factors, including contamination
in lairage, can alter the microbial populations present on cattle
hides at harvest (50, 51). Clearly, studies on the prevalence, con-
centrations, and genotypes of ESCr E. coli on cattle hides when
processing begins and in final products from the same processing
location are required for a complete understanding of frequency
and sources of the ESCr E. coli contamination of beef products.
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Supplemental Table S1. Statistical comparison of herd and IDS+TIO ESCR E. coli prevalences
Period
Number 
sampled
% prevalence 
ESCR E. coli Period
Number 
sampled
% prevalence 
ESCR E. coli
Fecal Increased disease susceptibility 128 5.5 Increased disease susceptibility, pre-ceftiofur injection 49 8.2 0.50
Fecal Increased disease susceptibility 128 5.5 Increased disease susceptibility, 3 to 8 days post-ceftiofur injection 50 92.0 < 0.01
Fecal December 2009 173 2.9 December 2009 49 6.1 0.38
Fecal March 2010 178 1.7 March 2010 48 0.0 1.00
Fecal May 2010 178 2.2 May 2010 48 2.1 1.00
Fecal July 2010 178 11.2 July 2010 48 2.1 0.05
Hide Increased disease susceptibility 128 11.7 Increased disease susceptibility, pre-ceftiofur injection 49 8.2 0.60
Hide Increased disease susceptibility 128 11.7 Increased disease susceptibility, 3 to 8 days post-ceftiofur injection 50 26.0 0.02
Hide December 2009 173 7.5 December 2009 49 24.5 < 0.01
Hide March 2010 178 1.7 March 2010 48 0.0 1.00
Hide May 2010 178 17.4 May 2010 48 20.8 0.67
Hide July 2010 178 8.4 July 2010 48 0.0 0.05
Sample 
type
Herd IDS+TIO 
P value
Period
Number 
sampled
% prevalence 
ESCR E. coli Period
Number 
sampled
% prevalence 
ESCR E. coli
Fecal December 2009 173 2.9 December 2009 33 3.0 1.00
Fecal March 2010 178 1.7 March 2010 39 0.0 1.00
Fecal May 2010 178 2.2 May 2010 43 0.0 1.00
Fecal July 2010 178 11.2 July 2010 51 9.8 1.00
Hide December 2009 173 7.5 December 2009 33 9.1 0.73
Hide March 2010 178 1.7 March 2010 39 2.6 0.55
Hide May 2010 178 17.4 May 2010 43 25.6 0.28
Hide July 2010 178 8.4 July 2010 51 3.9 0.37
Supplemental Table S2. Statistical comparison of herd and Other+TIO ESCR E. coli prevalences     
Herd
Sample 
type
Other+TIO 
P value 
